Standing out in the field of IgY Immunotechnology

  • Home
    Home A full collection of all the Research Archive entries.
  • Years
    Years Sort entries by year.
  • Tags
    Tags Displays a list of tags that have been used in the blog.
  • Archives
    Archives Contains a list of research entries that were created previously.

FSH stimulates ovarian cancer cell growth by action on growth factor variant receptor*

Posted by on in 2007
  • Font size: Larger Smaller
  • Hits: 2383
  • Print

Lia, Y, S. Gantaa, C. Chengb, R. Craiga, R.R. Gantab and L.C. Freemana, 2007, Mol. Cell. Endocrinol. 267: 26-37.

aDepartment of Anatomy & Physiology, Kansas State University, Manhattan, KS 66506, United States bDepartment of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS 66506, United States


A number of FSH receptor (FSH-R) isoforms with distinct structural motifs and signaling paradigms have been described, including a single transmembrane domain variant that functions as a growth factor type receptor (FSH-R3). This study tested the hypothesis that FSH can stimulate ovarian cancer cell proliferation by acting on FSH-R3, using the tumorigenic mouse ovarian surface epithelial cell (MOSEC) line ID8. FSH enhanced ID8 proliferation in a concentration-dependent fashion. Moreover, FSH-treatment of ID8 elicited intracellular events consistent with activation of FSH-R3 and distinct from those associated with activation of the canonical G-protein coupled FSH-R isoform (FSH-R1). Specifically, the FSH-R3 signaling pathway included cAMP-independent activation of ERK downstream of an SNX-482 sensitive component likely to be the Cav2.3 calcium channel. Northern analysis using probes specific for exons 7 and 11 of FSH-R identified consistently only one 1.9 kb transcript. Immunoblot analysis confirmed expression of FSH-R3 but not FSHR-1 in ID8. Together, these data suggest that FSH-R3 signaling promotes proliferation of ovarian cancer cells.

*Custom peptides and IgY antibodies used in this publication were produced by Gallus Immunotech Inc. Please visit our Custom Peptide Synthesis and Custom IgY production pages for more information.

Last modified on